



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Bo

Search PubMed for

Limits Preview/Index History Clipboard Details

About Entrez

Abstract   Text

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

PubMed Services

Journal Browser

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Curr Opin Mol Ther 2001 Jun;3(3):288-94

Related Articles, **NEW Books**

### Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.

Orr RM.

CRC Centre for Cancer Research, The Institute of Cancer Research, Sutton, Surrey, UK. rosanne@icr.ac.uk

Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide with sequence complementarity to the coding region of the major immediate-early gene of human cytomegalovirus (CMV). Developed by Isis Pharmaceuticals Inc, fomivirsen is the first antisense oligonucleotide to receive approval for licensing and is marketed by Novartis' CIBA Vision. Fomivirsen is administered by intravitreal injection to AIDS patients for the treatment of CMV-induced retinitis. In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis [296420], [296780], and both European and Brazilian registration approval followed in the summer of 1999 [335238].

PMID: 11497353 [PubMed - in process]

Abstract   Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Freedom of Information Act | Disclaimer

i686-pc-linux-gnu Feb 4 2002 11:36:43